When most investors, including the pros, all agree on something, they're usually wrong. - Carl Icahn
A common bioscience investment theme is a "market overreaction," especially during this coronavirus bear market. Driven by unreasonable fear, the market knocks down promising growth stocks. That's to say, the strong earnings and fundamental development do not matter in the near term. Nonetheless, they're all that mattered in the long haul.
That being said, Clovis Oncology (CLVS) exemplifies the aforesaid phenomenon. Accordingly, Clovis recently published a strong earnings report. And yet, the coronavirus bear market clobbered the